Skip to main content

Mono Bar

Subsite Title

Publications and Digital Products

Cart

Store Navigation

Share Buttons

Page title

Advisory: Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update

Main page content

In stock for ordering

This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.

Publication ID
SMA16-4938
Publication Date
March 2016
More like this SAMHSA Advisory

Order Print Publication

Max Order Limit
25

You May Also Be Interested In

Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs

This guide informs clinicians about medications for opioid use disorder treatment, including side effects, drug interactions, and take-home doses. It discusses patient counseling, associated medical issues, hepatitis C evaluation, drug testing, and pregnant women.

The Facts about Buprenorphine for Treatment of Opioid Addiction

This brochure informs patients about buprenorphine and medication-assisted treatment for opioid use disorder. It describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.

Pharmacologic Guidelines for Treating Individuals with Post-Traumatic Stress Disorder and Co-Occurring Opioid Use Disorders

This manual offers guidelines for medication-assisted treatment for people, particularly veterans, living with post-traumatic stress disorder and co-occurring opioid use disorders. It covers screening, concomitant treatment, pharmacotherapy, and multiple misused substances.

Behavioral Health Equity Barometer, 2014

This report provides a snapshot of key aspects of behavioral health, serious mental illness, suicidal thoughts, and mental illness, substance use disorders, or both. The information is based on selected determinants of health, including race and ethnicity, income level, geography, and health insurance status.

TIP 63: Medications for Opioid Use Disorder - Full Document

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

TIP 63: Medications for Opioid Use Disorder - Executive Summary

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.